Best Proteasome Inhibitor for multiple myeloma
3 Proteasome Inhibitor drugs used for multiple myeloma, ranked by our independent rating. Compare them with all treatments for multiple myeloma or the full Proteasome Inhibitor class. Not medical advice — always consult a professional.
Quick answer: Of the 3 proteasome inhibitor drugs we rate for multiple myeloma, none are yet flagged as generics in our price data, and most are injectable. Our ranking reflects each drug’s FDA recall-safety record — not clinical effectiveness for multiple myeloma; the right choice depends on your situation, so confirm it with your prescriber.
Other drug classes for multiple myeloma
Top proteasome inhibitor for multiple myeloma: 1. Kitprozy · 2. Kyprolis · 3. Velcade
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | Not yet rated | Prescription | Injectable | No data | — | View → | |
| 2 | Not yet rated | Prescription | Injectable | No data | — | View → | |
| 3 | Not yet rated | Prescription | Injectable | No data | — | View → |
Full ranking · 3 drugs
kitprozy
PrescriptionFDA-sourced
Kitprozy (Carfilzomib) is a proteasome inhibitor used to treat Multiple Myeloma.
Price varies
kyprolis
PrescriptionFDA-sourced
Kyprolis (Carfilzomib) is a proteasome inhibitor used to treat Multiple Myeloma.
Price varies
velcade
PrescriptionFDA-sourced
Velcade (Bortezomib) is a proteasome inhibitor used to treat Multiple Myeloma, Mantle-Cell Lymphoma.
Price varies
Frequently asked
- What is the best proteasome inhibitor for multiple myeloma?
- Ratings are based on FDA regulatory recall-safety data — always consult a professional.
- Which proteasome inhibitor drugs treat multiple myeloma?
- pharmaranks lists 3 Proteasome Inhibitor products used for multiple myeloma, per NIH RxClass drug-classification data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.